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our study, flucytosine levels were not monitored, 
but patients had regular blood counts and elec-
trolyte and creatinine measurements. We showed 
that in a resource-constrained setting, in combi-
nation with amphotericin B, flucytosine can be 
used safely and increases both survival and fun-
gal clearance. Patients receiving the combination 
treatment had similar rates of adverse events as 
those receiving amphotericin B monotherapy. 
Fluconazole combined with flucytosine, recom-
mended as second-line treatment by the WHO, is 
an attractive treatment for cryptococcal meningi-
tis because of ease of administration.1 Flucona-
zole is cheaper than amphotericin B and has a 
favorable toxicity profile. However, amphotericin 
B–sparing combinations consistently show lower 
rates of yeast clearance from cerebrospinal fluid 
— early fungicidal activity — than those con-
taining amphotericin B.2 Bicanic and colleagues 
found that early fungicidal activity was closely 
correlated with survival.3 Therefore, in addition 
to improving access to flucytosine, it is impera-
tive that stakeholders work to improve the avail-
ability of, and the capacity to safely administer, 
amphotericin B.
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Ischemic	Heart	Disease	after	Breast	Cancer	Radiotherapy
To the Editor: In their analysis of ischemic 
heart disease in a Nordic cohort of survivors of 
breast cancer, Darby et al. (March 14 issue)1 ob-
serve a significant excess relative risk associated 
with radiotherapy, which is concordant with the 
risks seen in other radiotherapy-treated groups2,3 
(Table 1). This finding suggests that the mean 
dose to the heart is the most relevant metric for 
predicting radiation-associated ischemic heart 
disease. The findings about the radiation risks 
also agree with those of a recent meta-analysis4 
of low-to-moderate radiation exposure (Table 1), 
implying little sparing effect of low doses and 
protracted radiation exposures. The comprehen-
sive analysis by Darby et al. of other risk factors 
for ischemic heart disease suggests minimal in-
teraction with radiogenic risk, again consistent 
with (more limited) observations reviewed else-
where.4
All these findings suggest that there is excess 
ischemic heart disease associated with high 
(therapeutic) and low (diagnostic) doses of ra-
diation. Although there has been concern about 
increased risks of cancer associated with com-
puted tomographic (CT) angiograms and coro-
nary-artery calcium scans,6 the evidence pre-
sented by Darby et al. and elsewhere5 strongly 
suggests that clinicians should also be con-
cerned with cardiovascular morbidity and should 
limit the dose of radiation affecting the heart.
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To the Editor: In their study on the risk of is-
chemic heart disease among women after radio-
therapy for breast cancer, Darby et al. found that 
the rates of major coronary events increased lin-
early with the mean dose to the heart by 7.4% per 
gray. In the definition of major coronary events, 
death from ischemic heart disease was included 
according to specific codes. However, the deaths 
of patients with valvular disease, specifically 
those with aortic valvular disease, cannot be ex-
cluded. It has been shown that valvular disease, 
especially aortic stenosis, is a well-recognized 
complication of radiation therapy.1-3
The following findings could support the role 
of valvular disease in deaths from ischemic 
causes. The percentage increase per gray in the 
rate of major coronary events and the percentage 
increase according to time since radiation expo-
sure in the same events were similar among 
women with and those without risk factors for 
coronary artery disease. Thus, the effect of val-
Table	1.	Estimated	Excess	Relative	Risk	of	Heart	Disease	in	Groups	Exposed	to	Radiation.*
Study
Average	Dose	
to	Heart Cohort End	Point
Excess	Relative	Risk	
(95%	CI)†
Sv (range) Sv−1
High-dose	exposure
Nordic breast cancer  
case–control study1
4.9 (0.03 to 27.72) 963 case patients  
and 1205 controls
Ischemic heart 
 disease‡
0.074 (0.029 to 0.145)
French–U.K. childhood 
 cancer study5
11.1 (<1 to >15)§ 4122 persons with 
 survival at 5 yr 
Death from any 
 cardiovascular  
disease
0.6 (0.2 to 2.5)
U.S. Childhood Cancer 
Survivor Study3
NA (<5 to >35) 14,358 patients Myocardial infarction 0.04 (−0.02 to 0.10)¶
Peptic ulcer study2 1.01 (0.0 to 6.20) 3600 patients, with 
76,571.7 person-yr 
of follow-up
Death from coronary 
heart disease‖
0.102 (0.039 to 0.174)
Low-	or	moderate-dose	
	exposure
Meta-analysis4 <0.5 (0 to 5.92) 451,386 patients** Ischemic heart dis-
ease or death 
from ischemic 
heart disease‡
0.10 (0.04 to 0.15)††
* Adapted from Little et al.4 Moderate or high exposure was defined as a mean exposure of the heart to 0.5 Sv or more, 
and low or moderate exposure was defined as a mean exposure of the heart to less than 0.5 Sv. Unless otherwise 
specified, all end points are for morbidity. CI denotes confidence interval, and NA not available.
† Values shown are for the excess relative risk per sievert of radiation exposure.
‡ Ischemic heart disease was defined with the use of International Classification of Diseases, 10th Revision, codes I20–I25.
§ The value represents the mean dose to the heart in 21 persons who died of cardiovascular disease.
¶ The estimate was derived by fitting a linear model by weighted least squares, applied to the aggregate data provid-
ed in Table 4 of Mulrooney et al.3 We assumed average cardiac doses of 0 Gy, 2.5 Gy, 10 Gy, 25 Gy, and 40 Gy in the 
respective groups with the following specified ranges of cardiac doses: 0 Gy, more than 0 to less than 5 Gy, 5 Gy or 
more to less than 15 Gy, 15 Gy or more to less than 35 Gy, and 35 Gy or more.
‖ Coronary heart disease was defined with the use of International Classification of Diseases, 8th Revision, codes 410–414.
** The value for the meta-analysis excludes the numbers in three cohorts (Laurent et al., 2010; Muirhead et al., 2009; 
and Yamada et al., 2004) because of overlap with other studies.4
†† The value was calculated with the use of a random-effects model; as calculated with the use of a fixed-effects model, 
the value was 0.10 (0.05 to 0.15).
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vular disease on the rate of death from ischemic 
causes needs to be further analyzed in the study 
by Darby et al.
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To the Editor: Darby et al. assess rates of car-
diovascular events and death in a large, well-
studied cohort. However, we question the indi-
vidual estimates of dose, because their virtual 
simulation and planning reconstructed “each ra-
diotherapy regimen on the CT scan of a woman 
with typical anatomy” with the use of the calcu-
lations of a single case as the reference.1
Table 1 shows the results of a study compar-
ing dosimetry of CT-based simulation in the 
supine and prone positions for 400 patients with 
breast cancer. Considerable anatomical variabil-
ity is reflected by the volume range of the organs 
at risk included in the treatment fields of breast 
radiotherapy.3 The in-field volume receives the 
full dose and is an excellent surrogate for nor-
mal tissue exposure to breast radiotherapy.3 The 
prone position enabled lower mean doses to the 
heart and lung, as compared with the supine 
position.3 In the same group of patients, we 
found that the prone position limits the mean 
dose to the heart to approximately 1 Gy for pa-
tients with left-sided breast cancer and 0.6 Gy 
for those with right-sided breast cancer.3 Indi-
vidual CT-derived dose distributions are war-
ranted in order to prove associations with car-
diovascular events.4
Silvia C. Formenti, M.D. 
Stella C. Lymberis, M.D. 
J. Keith DeWyngaert, Ph.D.
New York University Langone Medical Center 
New York, NY 
silvia.formenti@nyumc.org
No potential conflict of interest relevant to this letter was re-
ported.
1.	 Taylor CW, Povall JM, McGale P, et al. Cardiac dose from 
tangential breast cancer radiotherapy in the year 2006. Int J Ra-
diat Oncol Biol Phys 2008;72:501-7.
2.	 Lymberis SC, DeWyngaert JK, Parhar P, et al. Prospective 
assessment of optimal individual position (prone versus supine) 
for breast radiotherapy: volumetric and dosimetric correlations 
in 100 patients. Int J Radiat Oncol Biol Phys 2012;84:902-9.
3.	 Formenti SC, DeWyngaert JK, Jozsef G, Goldberg JD. Prone 
vs supine position for breast cancer radiotherapy. JAMA 2012; 
308:861-3.
4.	 Chung E, Corbett JR, Moran JM, et al. Is there a dose-rela-
tionship for heart disease with low-dose radiation therapy? Int J 
Radiat Oncol Biol Phys 2013;85:959-64.
DOI:	10.1056/NEJMc1304601
Table	1.	Volume	Results	for	In-Field	Heart	and	Lung	in	400	Patients	with	Breast	Cancer,	According	to	Position	
for	Radiotherapy.*
In-Field	Organ Supine	Position Prone	Position
Mean (95% CI) Range Mean (95% CI) Range
cubic centimeters of in-field volume
Left-sided breast cancer
Heart 8.75 (6.53–10.97) 0–134.75 1.25 (0.66–1.84) 0–41.02
Lung 98.58 (88.77–108.39) 0–334.57  8.73 (5.42–11.74) 0–228.27
Right-sided breast cancer
Heart 0 NA 0 NA
Lung 121.38 (110.44–132.32) 0–464.77   16.78 (13.14–20.41) 0–201.05
* A total of 200 patients with cancer of the left breast and 200 with cancer of the right breast participated in a prospec-
tive clinical trial that received approval from an institutional review board; each patient underwent CT-based simula-
tion in both the supine and prone positions. The prone position resulted in a reduced mean dose of radiation to the 
heart and lung.2 The 95% confidence interval (CI) was calculated on the basis of paired t-statistics. NA denotes not 
applicable.
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To the Editor: Darby et al. describe the risk of 
coronary events among patients with breast can-
cer treated with radiation between 1958 and 
2001. The modern reality is that radiation-deliv-
ery techniques have improved substantially. Cur-
rently, with the use of breath hold for patients 
with more than 10 cm3 of cardiac volume treated 
(15% of the breast-cancer population), the mean 
dose to the heart can be reduced considerably 
from 3.2 Gy to 1.3 Gy.1 The remaining 85% of 
patients receive even lower cardiac doses. Figure 2 
of the article indicated that even with a mean 
heart dose of 3 Gy, the increase in heart disease 
caused by radiation would be 0.9 percentage 
points; for women with cardiac risk factors, the 
risk increased by only 1.7 percentage points.
It is important to reassure women with breast 
cancer that with the use of current technologies, 
the cardiac dose can be decreased considerably, 
and cardiac risk factors can be better managed. 
The recent meta-analysis by the Early Breast 
Cancer Trialists’ Collaborative Group observed 
an improvement of 3% in overall survival for 
patients undergoing breast radiotherapy,2 under-
scoring that the risk–benefit ratio remains in 
favor of radiation treatment.
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To the Editor: Darby et al. discuss cardiac toxic 
effects that were seen within 4 years after radio-
therapy for early breast cancer. From 2000 
through 2012, in the Targeted Intraoperative Ra-
diotherapy Alone (TARGIT-A) randomized trial,1 
investigators evaluated 3451 patients with breast 
cancer who were 45 years of age or older and who 
had unifocal invasive ductal carcinoma with a di-
ameter of 3.5 cm or less. The study showed that 
a single dose of targeted intraoperative radio-
therapy as part of a risk-adapted strategy given at 
the time of lumpectomy and focused to the tu-
mor bed, which completely excluded the heart 
and other organs, achieved ipsilateral breast-
tumor control that was noninferior to external-
beam radiotherapy to the whole breast. The 
planned analysis of survival,2 which included 36 
deaths from breast cancer and 52 deaths not re-
lated to breast cancer, showed a significantly 
lower rate of death from causes not related to 
breast cancer with targeted intraoperative radio-
therapy, as compared with external-beam radio-
therapy (hazard ratio, 0.47; 95% confidence in-
terval [CI], 0.26 to 0.84; P<0.009). This reduction 
in deaths with targeted intraoperative radiother-
apy was driven by fewer deaths from cardiovas-
cular causes and other cancers. This level-one 
evidence suggests that for patients who have tu-
mors with a good prognosis, it is important to 
ensure that our treatments do not increase the 
risk of death not caused by breast cancer. Targeted 
intraoperative radiotherapy appears to achieve 
this while maintaining cancer control. In addi-
tion, it has been shown to have a beneficial effect 
on the wound microenvironment,3 and perhaps 
this effect could spill over, causing favorable sys-
temic effects.4
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The Authors Reply: We agree with Little et al. 
that clinicians should be aware of the risk of car-
diovascular morbidity and limit the dose to the 
heart when performing radiotherapy for breast 
cancer. As pointed out by Liu et al., many radio-
therapy centers already do this by means of tech-
niques such as breath hold, by treating patients 
in the prone position (as indicated by Formenti 
et al.), or by intraoperative radiotherapy (as indi-
cated by Vaidya et al.). We agree with Liu et al. 
that a comparison of benefits and risks is impor-
tant in radiotherapy for breast cancer. As dis-
cussed in our article, the results of our study pro-
vide reassurance for the majority of patients that 
their absolute risk of heart disease from radio-
therapy is likely to be small, as compared with 
the probable absolute benefit from radiotherapy.1 
Our results can also be used to identify the mi-
nority of patients for whom the benefits of radio-
therapy do not clearly outweigh the risks.
In the cohort study2 preceding our case–con-
trol study, we compared patients who underwent 
radiotherapy for the treatment of cancer of the 
left breast with those treated for cancer of the 
right breast, and we found an increased risk of 
aortic valvular disease among those with cancer 
of the left breast, with an incidence-rate ratio 
of 1.70 (95% CI, 1.14 to 2.53; P = 0.009). Valvular 
disease was not a case-defining event in our 
case–control study, but in response to Toutouzas 
et al., we note that the study of valvular disease 
will require further work.
Formenti et al. comment on the method we 
used to estimate individual patient doses. Al-
most all the women who were included in our 
study were treated before the era of radiotherapy 
planning with the use of patient-specific scans 
based on CT, so our dose estimates could not 
take into account differences in anatomy. If we 
had been able to do so, it is likely that our esti-
mated risks per gray would have been somewhat 
larger, but we do not know by how much. In 
order to identify the best possible treatment for 
each patient, clinicians need information on the 
absolute size of the benefits and on the absolute 
size of the risks. Our research group is continu-
ing to develop methods to estimate the conse-
quences of the cardiac doses delivered by old 
radiotherapy regimens, so that the experience of 
patients treated in the past can be used to pro-
vide clinicians with information on the absolute 
magnitude of the risks of current cancer treat-
ments.
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Omalizumab	for	Chronic	Urticaria
To the Editor: Maurer et al. (March 7 issue)1 
report the results of a phase 3 trial of omaliz-
umab for the treatment of urticaria. Figure 1 of 
their article shows that withdrawals from the 
study because of “disease progression” occurred 
only in patients who received omalizumab; there 
were no withdrawals due to disease progression 
in the placebo group. Furthermore, the percent-
age of patients who withdrew due to disease pro-
gression correlated with the dose of omalizumab 
(1% in the 75-mg group, 4% in the 150-mg group, 
and 8% in the 300-mg group); this suggests that 
omalizumab may itself, paradoxically, contribute 
to urticaria.
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